Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04560257
Other study ID # LGH004
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2020
Est. completion date December 30, 2020

Study information

Verified date December 2020
Source Lahore General Hospital
Contact Muhammad Irfan Malik, FCPS
Phone 03334367220
Email drmirfanmalik@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Many non-invasive ventilatory choices are available for COVID-19 patient who are having mild to moderate respiratory distress and their use will decrease the chance of ICU admission, intubation and mechanical ventilation in severe cases of COVID-19. However, all these respiratory supports and oxygen supply devices are aerosol generating and their selection should be precised enough to control nosocomial spread. High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen. In acute respiratory failure HFNC is proven to be very effective and it also reduced the need of mechanical ventilation in severe patients. Apart from the supply of oxygen, HFNC generating positive airway pressure and decreasing the rebreathing from anatomical dead space. Prone position is also a save therapy and has been proven to be effective for refractory hypoxia by increasing tidal volume, oxygenation and diaphragmatic functions in ARDS patients. Recent studies showed that prone positioning and HFNC might avoid the prerequisite of intubation in moderate to severe patients of ARDS and as a result it decreases the nosocomial infection in physicians who are doing these aerosol generating procedures.


Description:

This is observational single-center study, that will be done at Lahore General Hospital in which 95 beds are allocated for COVID-19 patients including ICUs and HDUs. Ethical approval will be obtained from research ethical committee of Lahore General hospital, Lahore. Informed consent will be obtained from all patients who will agree to publish their data in this research. We will protect patient's privacy and obey with the Helsinki Declaration.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 30, 2020
Est. primary completion date December 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - All patients of > 18 years of ages, males and females who will be diagnosed COVID-19 positive by RT-PCR with moderate illness. - Patients having classical radiological lesions of COVID-19 on X-ray chest or HRCT chest. - Respiratory rate > 30/ min and not responding to non-rebreather masks. - COVID-related pneumonia requiring non-invasive ventilatory support (high-flow nasal cannula, and / or non-invasive ventilation and / or CPAP) Exclusion Criteria: - Inability to provide consent; - Severe respiratory failure requiring invasive ventilatory support; - Indication of immediate tracheal intubation - Significant acute progressive circulatory insufficiency - Impaired alertness, confusion, restlessness - Chest trauma or other contraindication to prone position - Pneumothorax - Nasal blockade - Unable to tolerate high flow oxygen

Study Design


Related Conditions & MeSH terms


Intervention

Device:
High flow nasal cannula HFNC
High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen.

Locations

Country Name City State
Pakistan Muhammad Irfan Malik Lahore Punjab

Sponsors (1)

Lead Sponsor Collaborator
Lahore General Hospital

Country where clinical trial is conducted

Pakistan, 

References & Publications (4)

Pinkham M, Tatkov S. Effect of flow and cannula size on generated pressure during nasal high flow. Crit Care. 2020 May 24;24(1):248. doi: 10.1186/s13054-020-02980-w. — View Citation

Richards M, Le Roux D, Cooke L, Argent A. The Influence of High Flow Nasal Cannulae on the Outcomes of Severe Respiratory Disease in Children Admitted to a Regional Hospital in South Africa. J Trop Pediatr. 2020 Dec 1;66(6):612-620. doi: 10.1093/tropej/fmaa024. — View Citation

Tu GW, Liao YX, Li QY, Dong H, Yang LY, Zhang XY, Fu SZ, Wang RL. Prone positioning in high-flow nasal cannula for COVID-19 patients with severe hypoxemia: a pilot study. Ann Transl Med. 2020 May;8(9):598. doi: 10.21037/atm-20-3005. — View Citation

Whittle JS, Pavlov I, Sacchetti AD, Atwood C, Rosenberg MS. Respiratory support for adult patients with COVID-19. J Am Coll Emerg Physicians Open. 2020 Apr 13. doi: 10.1002/emp2.12071. [Epub ahead of print] — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical response of HFNC The number of patients treated with non-invasive ventilation devices. HFNC related events (hot air feeling, nasal lesions) 10 days
Secondary Duration of intervention Length of HFNC therapy to COVID-19 patients 15 days
Secondary Duration of hospitalization Number of days of hospital admission either in ICU or HDUs till date of discharge 15 days
Secondary Supplemental Oxygen Requirement from Baseline Duration of increased supplemental oxygen requirement from baseline 15 days
Secondary Radiological outcome Follow up radiological response HR-CT. 15 days
See also
  Status Clinical Trial Phase
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546776 - COVID-19 Persistence in Stool
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Recruiting NCT04615052 - Home-based Exercise in COVID-19 Survivors N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Recruiting NCT04885452 - Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
Completed NCT04516928 - Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel
Completed NCT05063812 - Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
Completed NCT04530357 - Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine Phase 1/Phase 2
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Completed NCT04733625 - The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection N/A
Completed NCT04550390 - Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19
Active, not recruiting NCT04517136 - Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions
Recruiting NCT04476680 - Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion N/A
Completed NCT04839913 - Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study
Completed NCT04514874 - Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020
Terminated NCT04606563 - Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? Phase 3
Completed NCT05234359 - The CHILD Cohort COVID-19 Add-On Study